NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>NHMRC</strong> GUIDELINES FOR THE SCREENING, PROGNOSIS, DIAGNOSIS, MANAGEMENT AND PREVENTION OF GLAUCOMA<br />
Chapter 9 – Medication<br />
beta-blockers should not be used together with verapamil, diltiazem or digoxin (unless under<br />
specialist cardiac supervision). If a calcium channel blocker must be used, beta-blockers can be<br />
used safely with dihydropyridines (i.e. amlodipine, nifedipine, nimodipine) as they have little to<br />
no effect on cardiac conduction. However, the potentially additive hypotensive effect remains.<br />
It is important to note that the use of beta-blockers is contraindicated in patients with bradycardia<br />
(45–50 beats/minute), sick sinus syndrome, second or third degree atrioventricular block, severe<br />
hypotension or uncontrolled heart failure (AMH 2009). Beta-blockers may also impair peripheral<br />
circulation and exacerbate symptoms of severe peripheral vascular disease and Raynaud’s syndrome.<br />
Alpha 2<br />
-agonists should be used with caution in patients with severe cardiovascular disease as these<br />
medications may worsen symptoms (AMH 2009). Other medications used in the management of<br />
glaucoma are safe in patients with cardiovascular disease.<br />
Evidence Statements<br />
• Evidence indicates using alpha 2<br />
-agonists with caution in patients with severe cardiovascular disease.<br />
A specialist cardiac opinion may be required for individual cases.<br />
• Evidence indicates using beta-blockers with caution in patients with existing heart disease. Using these<br />
medications is contraindicated in patients with bradycardia (45–50 beats/minute), sick sinus syndrome,<br />
second or third degree atrioventricular block, severe hypotension or uncontrolled heart failure.<br />
Hepatic impairment<br />
Systemic use of acetazolamide (carbonic anhydrase inhibitor) is contraindicated in patients<br />
with hepatic impairment or cirrhosis, due to the risk of hepatic encephalopathy (AMH 2009).<br />
The manufacturers of topical carbonic anhydrase inhibitors (dorzolamide and brinzolamide)<br />
advise using them with caution in patients with hepatic impairment, as these medications have<br />
not been adequately studied in this patient group.<br />
Evidence Statement<br />
• Evidence indicates that systemic carbonic anhydrase inhibitors are contraindicated in patients with<br />
hepatic impairment, while topical carbonic anhydrase inhibitors may be used with caution.<br />
Renal impairment<br />
Systemic use of acetazolamide, a carbonic anhydrase inhibitor, is contraindicated in patients with<br />
severe renal impairment (i.e. when CrCl < 10 mL/minute) as there is an increased risk of profound<br />
acidosis. In patients with moderate renal impairment it is recommended that the dose be reduced<br />
(i.e. when CrCl between 10-30 mL/min) (AMH 2009). It is also important to note that acetazolamide<br />
increases the risk of urolithiasis (kidney stones).<br />
There is much less information available about the use of topical carbonic anhydrase inhibitors<br />
in patients with renal impairment. The manufacturers of topical carbonic anhydrase inhibitors<br />
(dorzolamide and brinzolamide) recommend against using them in patients with severe renal<br />
impairment, as they have not been adequately studied in this patient group. Therefore, as<br />
systemic absorption does occur, the same precautions should be followed as for the systemic use<br />
of acetazolamide.<br />
126 National Health and Medical Research Council